drugset
Drugs / HB1801
last change Jul 2026 re-read 2 minutes ago

HB1801

also known as docetaxel
Developed for
HER2 positive breast carcinoma · non-small cell lung carcinoma · breast cancer · breast carcinoma by gene expression profile · female breast carcinoma · hormone receptor-positive breast cancer
Investigated by
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Shanghai JMT-Bio Inc. · Fudan University

Trials 8 · a red edge is where a trial was stopped

today NCT07441460 · Ph 3 NCT07116824 · Ph 2 NCT07083505 · Ph 2 NCT06747338 · Ph 3 NCT06525350 · Ph 2 NCT05838066 · Ph 3 NCT05863325 · Ph 2 NCT05582499 · Ph 2
202320242025202620272028202920302031203220332034
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 25 trials
Phase 2 NCT07116824 Sep 2025 → Jul 2026 overdue HER2 positive breast carcinoma CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Not yet recruiting No outcome recorded
Phase 2 NCT07083505 Aug 2025 → Oct 2026 expected breast cancer CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Not yet recruiting No outcome recorded
Phase 2 NCT06525350 Jul 2024 → Dec 2026 expected non-small cell lung carcinoma CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Not yet recruiting No outcome recorded
Phase 2 NCT05863325 Jun 2023 → Mar 2024 non-small cell lung carcinoma CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Unknown No outcome recorded
Phase 2 NCT05582499 Nov 2022 → Dec 2027 expected HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma Fudan University Recruiting No outcome recorded
Phase 33 trials
Phase 3 NCT07441460 Mar 2026 → Aug 2034 expected HER2 positive breast carcinoma Shanghai JMT-Bio Inc. Recruiting No outcome recorded
Phase 3 NCT06747338 Dec 2024 → Dec 2026 expected HER2 positive breast carcinoma Shanghai JMT-Bio Inc. Active not recruiting No outcome recorded
Phase 3 NCT05838066 Jul 2023 → Jul 2025 overdue breast carcinoma by gene expression profile Shanghai JMT-Bio Inc. Recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06682611 Comparator Nov 2024 → Nov 2026 expected — Shanghai Runshi Pharmaceutical Technology Co., Ltd Not yet recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as HB1801 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05582499 ↗
8

NCT06747338 ↗

NCT07441460 ↗

NCT05863325 ↗

NCT05838066 ↗

NCT07116824 ↗

NCT06682611 ↗

NCT06525350 ↗

NCT07083505 ↗
Known as docetaxel “HB1801 is Docetaxel for injection (Albumin-bound).” NCT07083505 ↗
1

“HB1801 (docetaxel, albumin-bound）” NCT06525350 ↗
Route Intravenous “intravenous (IV) infusion” NCT05838066 ↗